Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Entera Bio Ltd.NASDAQ: ENTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $604K a year earlier. Trailing-twelve-month stock-based compensation was $0. Over 3 fiscal years it compounded at +7.0% a year.
Context
- Stock-based compensation amounted to 6547.6% of revenue in FY2025, up 5135.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.75M USD
- Year-over-year change
- +7.6%
- 4-year CAGR
- +10.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.75M | +7.6% |
| FY2024 | 2024-12-31 | 2.56M | +51.3% |
| FY2023 | 2023-12-31 | 1.69M | -24.8% |
| FY2022 | 2022-12-31 | 2.25M | +20.7% |
| FY2021 | 2021-12-31 | 1.86M | — |
Stock-Based Compensation vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's LTM Mar 2026 stock-based compensation of $0 is the smallest of the 10 companies compared; the peer median is $5M.
- Its year-over-year change of -100.0% is the lowest of 9, against a peer median of -43.8%.
- Over three fiscal years its annual growth of +7.0% compares with a peer median of -15.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $9.79M | -43.4% | -24.8% | 853.3% | |
| LTM Mar 2026 | $9.77M | +1.5% | +47.6% | — | |
| LTM Mar 2026 | $5M | — | +208.8% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Mar 2026 | $3.88M | -47.0% | -22.0% | 7.1% | |
| LTM Mar 2026 | $3.06M | -44.1% | -45.0% | — | |
| LTM Apr 2026 | $2.26M | -44.4% | -15.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | +7.0% | — | |
| Peer median (excluding ENTX) | $5M | -43.8% | -15.0% | 33.0% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| Deferred Income Tax | (217K) | 174K | 29K | 14K | 0 |
| Stock-Based Compensation | 1.86M | 2.25M | 1.69M | 2.56M | 2.75M |
| Change in Working Capital | 1.41M | (1.84M) | (195K) | 112K | 1.26M |
| Accounts Receivables | 72K | (63K) | 246K | (126K) | 126K |
| Inventory | (72K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 74K | (149K) | 66K | 49K | 316K |
| Other Working Capital | 1.34M | (1.62M) | (507K) | 189K | 815K |
| Other Non-Cash Items | 18K | (78K) | 1.69M | (5K) | 32K |
| Operating Cash Flow | (9.06M) | (12.5M) | (7.31M) | (6.82M) | (7.37M) |
| Capital Expenditures | (17K) | (47K) | (17K) | (3K) | (107K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (55K) | 0 | 0 | 0 |
| Investing Cash Flow | (17K) | (102K) | (17K) | (3K) | (107K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 21.81M | 13K | 6.62M | 3.96M | 13.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.58M | 0 | (580K) | 516K | 0 |
| Financing Cash Flow | 25.38M | 13K | 6.04M | 4.48M | 13.71M |
| Effect of Forex Changes | 0 | 5K | 0 | 0 | (10K) |
| Net Change in Cash | 16.3M | (12.58M) | (1.29M) | (2.35M) | 6.23M |
| Free Cash Flow | (9.08M) | (12.55M) | (7.33M) | (6.82M) | (7.48M) |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.